EANS-Adhoc: LifeWatch announces two major contracts in the first quarter 2012 (with document)

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Company Information/LifeWatch AG

28.03.2012

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss
Exchange: LIFE), the leading wireless cardiac monitoring service
provider in the U.S., announced today the completion of two new major
contracts in the first quarter 2012 for its cardiac monitoring
services and for its NiteWatch Home Sleep Testing with Prime/NAMM
and Dimension Health PPO respectively.

You will find a PDF-version of this press release at the end of this
message.

The demand for LifeWatch cardiac monitoring services in California is
accelerating. Major California contracts that were concluded in 2011
were Blue Shield of California and the Heritage Provider Network from
Southern California. This contract with PrimeCare from North American
Medical Management, California, Inc. (NAMM) is for cardiac monitoring
services including ACT. NAMM develops and manages provider networks
in California, offering a full range of services to assist physicians
and other providers in their managed care and business operations.
NAMM Clients represent a network of over 600 primary care physicians
and 1,200 specialists and work with the premier hospitals in their
respective markets. In total NAMM covers 205,000 lives.

The other contract is an agreement for NiteWatch Home Sleep Testing
with Dimension Health PPO, one of South Florida´s largest Preferred
Provider Organization (PPO) Networks. Dimension Health hospitals has
developed beginning in 1985 a high quality, cost effective, community
based network that insurers, employers, unions and government
sponsored health programs provide to their employees. Today Dimension
Health covers approximately 400,000 lives.

The contract with Dimension Health highlights a growing trend in the
U.S. healthcare industry. Currently, about 80 % of diagnostic testing
for Obstructive Sleep Apnea (OSA) is performed at expensive sleep
labs, and the remaining 20 % is performed at home. In early 2012,
Kaiser Health News (a non- profit news organization providing
in-depth coverage of American health care policy and politics)
associated the rising costs of diagnosing OSA with the overuse of
sleep labs. As more and more insurance companies like Dimension
Health become aware of the cost benefits of Home Sleep Tests to
diagnose OSA, the market is likely to experience a major shift from
Sleep Labs to the less expensive non-attended home sleep testing with
large insurers providing economic incentives for this paradigm shift.

"We are very excited about the continued validation of our superior
service to our customers in the very demanding California
marketplace. The acceptance for our cardiac monitoring services is
accelerating in California in no small part due to the addition of
our call center in San Francisco," stated Dr. Yacov Geva, Chairman
and CEO of LifeWatch AG. "And with Dimension Health we are able to
gain an important carrier in Florida for our NiteWatch Home Sleep
Testing service. We are sure that other private insurance companies
will follow this development."

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent
company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology
products. LifeWatch is also introducing a new program for Home Sleep
Testing of Obstructive Sleep Apnea (OSA) patients under the brand
name NiteWatch. For additional information, please visit
www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward- looking statements.
The words "believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions are intended
to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. All forward-looking
statements are based only on data available to LifeWatch AG at the
time of the issue of this press release. LifeWatch AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/JrNcWOXN

Further inquiry note:
Sensus Investor and Public Relations GmbH, Zürich:
Tel+41 433665511 | Fax+41 43 366 55 12| Email: lifewatch@sensus.ch

end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/JrNcWOXN

issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English